Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2002

01-07-2002 | Original Article

Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study

Authors: Robert E. Martell, Bercedis L. Peterson, Harvey Cohen, William P. Petros, Kanti R. Rai, Vicki A. Morrison, Laurence Elias, Lois Shepherd, John Hines, Richard A. Larson, Charles A. Schiffer, Herbert I. Hurwitz

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2002

Login to get access
Metadata
Title
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Authors
Robert E. Martell
Bercedis L. Peterson
Harvey Cohen
William P. Petros
Kanti R. Rai
Vicki A. Morrison
Laurence Elias
Lois Shepherd
John Hines
Richard A. Larson
Charles A. Schiffer
Herbert I. Hurwitz
Publication date
01-07-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0443-5

Other articles of this Issue 1/2002

Cancer Chemotherapy and Pharmacology 1/2002 Go to the issue

Original Article

Suicide gene therapy using E. coli β-galactosidase

Clinical Trial Report

Pilot study of gemcitabine (10 mg/m2 per min) and cisplatin

Original Article

A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling

Original Article

The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer

Original Article

Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells

Original Article

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits